# A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

> **NCT03235570** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 44 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT03235570
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2020-03-04
- **Final completion:** 2020-03-04
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2020-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03235570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03235570, "A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03235570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*